Skip to main content

Table 4 Risk of heart failure with DPP-4 inhibitors versus GLP-1 agonists in propensity score matched sensitivity analyses

From: Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists

Study population

Medications

Person-years

No. of HF events

Crude incidence (per 1000 person-years)

Adjusted HR of HF (95% CI)

Primary diagnosis only

DPP-4 inhibitors

77,070

3107

40

0.84 (0.80, 0.89)

GLP-1 agonists

70,706

3424

48

Reference

Extend follow-up to 45 days

DPP-4 inhibitors

94,201

5714

61

0.89 (0.85, 0.92)

GLP-1 agonists

89,315

6098

68

Reference

  1. CI confidence interval, DPP-4 dipeptidyl peptidase-4, GLP-1 glucagon-like peptide-1, HF heart failure, HR hazard ratio